CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 115 filers reported holding CYTOMX THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $0 | – | 102 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | – | 102 | 0.0% | 0.00% | – |
| Q1 2022 | $0 | – | 102 | 0.0% | 0.00% | – |
| Q4 2021 | $0 | -100.0% | 102 | 0.0% | 0.00% | – |
| Q3 2021 | $1,000 | 0.0% | 102 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | 0.0% | 102 | 0.0% | 0.00% | – |
| Q1 2021 | $1,000 | 0.0% | 102 | 0.0% | 0.00% | – |
| Q4 2020 | $1,000 | -50.0% | 102 | -64.2% | 0.00% | – |
| Q3 2020 | $2,000 | 0.0% | 285 | 0.0% | 0.00% | – |
| Q2 2020 | $2,000 | 0.0% | 285 | 0.0% | 0.00% | – |
| Q1 2020 | $2,000 | 0.0% | 285 | 0.0% | 0.00% | – |
| Q4 2019 | $2,000 | 0.0% | 285 | 0.0% | 0.00% | – |
| Q3 2019 | $2,000 | -33.3% | 285 | 0.0% | 0.00% | – |
| Q2 2019 | $3,000 | +50.0% | 285 | +34.4% | 0.00% | – |
| Q1 2019 | $2,000 | -33.3% | 212 | 0.0% | 0.00% | – |
| Q4 2018 | $3,000 | -25.0% | 212 | 0.0% | 0.00% | – |
| Q3 2018 | $4,000 | -20.0% | 212 | 0.0% | 0.00% | – |
| Q2 2018 | $5,000 | -16.7% | 212 | 0.0% | 0.00% | – |
| Q1 2018 | $6,000 | – | 212 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 5,803,700 | $25,130,000 | 0.91% |
| Altium Capital Management LP | 663,800 | $2,874,000 | 0.79% |
| Rubric Capital Management LP | 2,406,449 | $10,420,000 | 0.49% |
| RTW INVESTMENTS, LP | 6,029,700 | $26,109,000 | 0.38% |
| Orbimed Advisors | 3,214,509 | $13,919,000 | 0.18% |
| TANG CAPITAL MANAGEMENT LLC | 152,345 | $660,000 | 0.13% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 980,085 | $4,244,000 | 0.12% |
| Point72 Asset Management, L.P. | 6,303,025 | $27,292,000 | 0.11% |
| Sender Co & Partners, Inc. | 40,720 | $176,000 | 0.09% |
| Manteio Capital LLC | 15,067 | $65,000 | 0.08% |